News & Events

CAMBRIDGE, Mass. (January 4, 2022) – Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery and development of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Jay T. Backstrom, M.D., M.P.H., to its Board of Directors, and the appointment of Rahul Khara, Pharm.D., J.D., as General Counsel. Dr. Backstrom was most recently Executive Vice President, Head of Research and Development at Acceleron Pharma and Dr. K

Tomas Ganz, MD, PhD and Elizabeta Nemeth, PhD to Join Disc Medicine Scientific Advisory Board Cambridge, Mass. – October 13, 2020 – Disc Medicine, a company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced

More News

Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), expected March / April 2024 On track...


read more

Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024

WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and...


read more

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer

Pamela Stephenson is an accomplished industry executive with over 25 years of global commercial leadership experience and a track record of numerous...


read more